AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 11 - (NewsRx.com & NewsRx.net) -- Botswana is scheduled to begin tests on an AIDS vaccine to find out if it is safe when given to healthy adults, officials say.
The experimental vaccine, which has already been tested successfully on mice and rabbits, will be tested to determine the immune responses of healthy adults when the drug is given at different doses, said the Botswana Harvard AIDS Partnership for HIV Research and Education.
The vaccine, called EP HIV-1090, activates the CD8 or killer T cells in the immune system to destroy cells infected with HIV, the virus that causes AIDS.
The trials form the first phase of the process "to see if the vaccine is safe and well tolerated in humans," said Dr. Tony Villafana, the research site director.
The study, which is scheduled to last 18 months, will involve 42 HIV-negative volunteers from Botswana and the United States.
The test will use only subjects with high levels of the protein leukocyte antigen, or HLA, because it is found to be most responsive to the treatment.
The drug is made by Epimmune, based in San Diego.